Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research
-
By
-
Raphael Bertani
-
Fabio Torregrossa
-
Felipe Salvagni
-
June 17, 2026
-
Clinical Scorecard: New Approaches to Combat Glioblastoma: Progress in Research and Treatment
At a Glance
| Category | Detail |
|---|
| Condition | Glioblastoma (GBM) |
| Key Mechanisms | Genomic and epigenomic heterogeneity, immunosuppressive microenvironment, blood-brain barrier, diffuse infiltrative biology of glioma cells. |
| Target Population | Adults with glioblastoma. |
| Care Setting | Oncology and neurology clinics. |
Key Highlights
- Median overall survival for GBM remains around 15 months.
- Tumor-treating fields are the only addition to standard care showing survival benefit.
- Combination therapies may be necessary due to GBM's resistance mechanisms.
- Non-invasive detection methods for GBM are still under development.
- CSF detection rates for glioma are significantly higher than plasma.
Guideline-Based Recommendations
Diagnosis
- Utilize chromatin accessibility patterns from plasma cfDNA for glioma subtype classification.
- Consider CSF analysis for higher detection rates of mutations.
Management
- Explore combination therapies targeting multiple pathways in GBM treatment.
Monitoring & Follow-up
- Develop multi-layered diagnostic frameworks for monitoring GBM biology non-invasively.
Risks
- Systemic toxicity and poor blood-brain barrier penetration limit current therapeutic options.
Patient & Prescribing Data
Patients diagnosed with glioblastoma.
Current therapies have limited success; novel approaches are needed.
Clinical Best Practices
- Focus on combination therapies rather than monotherapies.
- Regularly assess the immunosuppressive microenvironment in GBM patients.
Related Resources & Content
